Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: A 6-month pilot study

Current Medical Research and Opinion

Volumn 23, Issue 12, 2007, Pages 3079-3089

  Racewicz, Artur J ^a,d   Schofield, Pamela J ^b   Cahall, David L ^c   Cline, Gary A ^b   Burgio, David E ^b  

^a NZOZ Centrum Medyczne   (Poland)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^c SANOFI   (France)

^d Centrum Medyczne Specjalistyczny Gabinet Lekarski Bialystok   (Poland)

Author keywords

Biological markers analysis; Bone mineral density; Bone resorption metabolism; Dose response relationship; Drug administration schedule; Osteoporosis, postmenopausal; Risedronate administration and dosage

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; PLACEBO; RISEDRONIC ACID; VITAMIN D;

ABDOMINAL PAIN; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASTROCYTOMA; BACKACHE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HUMAN; HYPERTENSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; PILOT STUDY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STROKE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COLLAGEN TYPE I; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 37749021342     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X242665     Document Type: Article

References (21)

1. National Osteoporosis Foundation. Disease facts [online]. Available from http://www.nof.org/osteoporosis/diseasefacts.htm/ [last accessed 22 February 2007]
2. Harris ST, Watts NB, Genant HK, et al.; for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. J Am Med Assoc 1999;282:1344-52
3. Reginster J, Minne HW, Sorensen OH, et al.; on behalf of the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91
4. McClung MR, Geusens P, Miller PD, et al.; for the Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. New Engl J Med 2001;344:333-40
5. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71:103-11 [Epub 2002 June 27]
6. Cramer JA, Lynch NO, Gaudin AF, et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 2006;28:1686-94
7. Ettinger MP, Gallagher R, MacCosbe PE. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 2006;12:522-8
8. Raisz L, Smith JA, Trahiotis M, et al. Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover. Osteoporosis Int 2000;11:615-20
9. FDA CDER. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Issued 4/1994 [online]. Available from http://www.fda.gov/cder/guidance/osteo.pdf/ [last accessed 22 February 2007]
10. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-6
11. Delmas PD, Eastell R, Garnero P, et al.; for the Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 2000;11 (Suppl 6):S2-S17
12. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004;20:433-9
13. Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;74:129-35 [Epub 2003 December 5]
14. Burgio DE, Russell DA, Desliva B, et al. Risedronate pharmacokinetics following daily (5 mg/day) and weekly (35 and 50 mg/week) oral dosing regimens to postmenopausal women. Clin Pharmacol Ther 2002;71:32 [Abstract ID357]
15. Mitchell DY, Eusebio RA, Sacco-Gibson NA, et al. Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. J Clin Pharmacol 2000;40:258-65
16. Singer FR, Clemens TL, Eusebio RA, Bekker PJ. Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease. J Clin Endocrinol Metab 1998;83:1906-10
17. Hosking DJ, Eusebio RA, Chines AA. Paget's disease of bone: reduction of disease activity with oral risedronate. Bone 1998;22:51-5
18. Miller PD, Brown JP, Siris ES, et al. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone [Paget's Risedronate/Etidronate Study Group]. Am J Med 1999;106:513-20
19. Siris ES, Chines AA, Altman RD, et al. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res 1998;13:1032-8
20. Brown JP, Hosking DJ, Ste-Marie L, et al. Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study. Calcif Tissue Int 1999;64:93-9
21. Delaney MF, Hurwitz S, Shaw J, LeBoff MS. Bone density changes with once weekly risedronate in postmenopausal women. J Clin Densitom 2003;6:45-50